Close Menu

North America

The year saw the launch of high-profile platforms as well as efforts by a number of parties to streamline mass spec technologies for the clinic.

The research highlighted particular challenges for gram-negative organisms among a population of higher-risk patients.

The court cited previous US Supreme Court rulings, including Mayo vs. Prometheus, in determining that certain claims of Illumina's patents were invalid.

Foundation Medicine's assay detects genomic alterations in 324 cancer genes and serves as a companion diagnostic for patients with certain types of tumors.

The infrared spectroscopy-based analyzer is designed to quantitatively measure the concentration of fat, carbohydrate, and protein in human milk.

The test is the second of three panels intended to detect pathogens that cause the bloodstream infections that can lead to sepsis.

New drugs, tests, and policies suggest steady and continued future growth in the space, though public awareness of personalized medicine continues to lag.

The assay uses a genomic DNA signature called the metastatic potential score derived from copy number alteration analysis of specific regions of the genome.

The firm anticipates deploying funds to complete the integration of Biosensia, a developer of multi-analyte assays on a CLIA-waived testing platform.

Molecular Testing Labs allegedly made payments to labs in exchange for Medicare and Tricare referrals between August 2014 and July 2015.

Pages